Objectives Pelvic vein embolisation is increasing in venous practice for the treatment of conditions associated with pelvic venous reflux. In July 2014, we introduced a local anaesthetic "walk-in walk-out" pelvic vein embolisation service situated in a vein clinic, remote from a hospital. Methods Prospective audit of all patients undergoing pelvic vein embolisation for pelvic venous reflux. All patients had serum urea and electrolytes tested before procedure. Embolisation coils used were interlock embolisation coils (Boston Scientific, USA) as they can be repositioned after deployment and before release. We noted (1) complications during or post-procedure (2) successful abolition of pelvic venous reflux on transvaginal duplex scanning (3) number of veins (territories) treated and number of coils used. Results In 24 months, 121 patients underwent pelvic vein embolisation. Three males were excluded as transvaginal duplex scanning was impossible and six females excluded due to lack of complete data. None of these nine had any complications. Of 112 females analysed, mean age 45 years (24-71), 104 were for leg varices, 48 vulval varices and 20 for pelvic congestion syndrome (some had more than one indication). There were no deaths or serious complications to 30 days. Two procedures were abandoned, one completed subsequently and one was technically successful on review. One more had transient bradycardia and one had a coil removed by snare during the procedure. The mean number of venous territories treated was 2.9 and a mean of 3.3 coils was used per territory. Conclusion Pelvic vein embolisation under local anaesthetic is safe and technically effective in a remote out-patient facility outside of a hospital.

Significant hepatic artery stenosis after liver transplantation can lead to thrombosis with associated high morbidity and mortality. The aim of our study is to evaluate our technical success rate, clinical outcomes and complications. Method(s): It's a retrospective study in 13 patients who underwent liver transplantation between 2010 and 2018. Recipients demographics, type of liver transplant, clinical presentations methods of diagnosing hepatic artery stenosis, types of anastomosis, approached for intervention, hepatic artery stenosis grading, primary angioplasty and in some cases assisted stenting were evaluated. All patients were assessed after intervention by clinical outcomes, Doppler examination. Result(s): Out of 13 patients, 5 patients after angioplasty were assisted by stenting, 11 patients have good flow (84%), in 1 patient no change in flow and 1 have poor flow,1 patient complicated by non flow limiting dissection, 1 underwent for surgical redo, 10 patients are still alive. Conclusion(s): Our results suggest hepatic artery angioplasty and stenting in liver recipients are minimally and safe procedures good alternative option to open surgeries.

and time to discontinuation is shown in table 1. There were no associated factors with time to discontinuation. Maintenance frequency of 12 weeks was half as likely to be associated with discontinuation, but not statistically significant. Only 8/44 on 8-weekly maintenance frequency de-escalated to 12weekly. Conclusion Only a third of CD patients discontinued ustekinumab at 2 years follow-up and 5% discontinued therapy between year 1 and 2 of treatment. This suggests clinical response within the first year of treatment is likely to be sustained for another year. None of the patient, disease or drugrelated factors predicted drug discontinuation.